0001209191-17-009043.txt : 20170209
0001209191-17-009043.hdr.sgml : 20170209
20170209160304
ACCESSION NUMBER: 0001209191-17-009043
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170207
FILED AS OF DATE: 20170209
DATE AS OF CHANGE: 20170209
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: aTYR PHARMA INC
CENTRAL INDEX KEY: 0001339970
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 203435077
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 3545 JOHN HOPKINS COURT, STE #250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-731-8389
MAIL ADDRESS:
STREET 1: 3545 JOHN HOPKINS COURT, STE #250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Amanullah Ashraf
CENTRAL INDEX KEY: 0001670631
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37378
FILM NUMBER: 17587538
MAIL ADDRESS:
STREET 1: C/O ATYR PHARMA, INC.
STREET 2: 3545 JOHN HOPKINS COURT, SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-02-07
0
0001339970
aTYR PHARMA INC
LIFE
0001670631
Amanullah Ashraf
3545 JOHN HOPKINS COURT, SUITE #250
SAN DIEGO
CA
92121
0
1
0
0
Vice President, Manufacturing
Employee Stock Option (right to buy)
3.30
2017-02-07
4
A
0
35000
0.00
A
2027-03-07
Common Stock
35000
35000
D
Restricted Stock Unit
2017-02-07
4
A
0
10000
0.00
A
Common Stock
10000
10000
D
The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
The restricted stock units (RSUs) are scheduled to vest in three equal annual installments beginning on February 7, 2018, such that the RSUs will fully vest on February 7, 2020. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Nancy D. Krueger, attorney-in-fact
2017-02-09